Drug Profile
Research programme: cell therapies - Juno Therapeutics
Alternative Names: STAGE Streptamer® Stem cells; STAGE Streptamer® T-regsLatest Information Update: 09 Mar 2018
Price :
$50
*
At a glance
- Originator Stage Cell Therapeutics
- Developer Juno Therapeutics
- Class Cell therapies; Stem cell therapies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Graft-versus-host disease
Most Recent Events
- 06 Mar 2018 Juno Therapeutics has been acquired by Celgene Corporation
- 16 Jul 2016 No recent reports of development identified for research development in Autoimmune-disorders in Germany (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Graft-versus-host-disease in Germany (Parenteral)